



## PRESS RELEASE

# CARMAT is participating in the 28<sup>th</sup> EACTS Annual Meeting in Milan (Italy)

## Presentation of the portable system project for patient home discharge

**Paris, October 9, 2014**

CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage heart failure, today announces its participation in the 28<sup>th</sup> [EACTS](#) (European Association for Cardio-Thoracic Surgery) Annual Meeting held in Milan (Italy) from October 11 to 15, 2014.

During the exhibition that will run in parallel to the scientific sessions from October 12 to 14, the Company will notably present, on its booth (#75-76), its portable system project<sup>1</sup>, the configuration that aims to allow patients who will have been implanted with its self-regulated bioprosthetic heart to leave hospital and return home under good conditions.

*"Being discharged from hospital and returning to their lives is very important for patients. The availability of our portable system will therefore be a major milestone for the Company", comments Marcello Conviti, CARMAT's CEO. He adds: "When a patient is discharged from hospital, not only does this have obvious economic benefits for healthcare systems, but – more importantly – the renewed quality of life that these portable systems could provide will play a key role in the adoption of our bioprosthesis by doctors and their patients."*



### **About CARMAT: the world's most advanced total artificial heart project**

**A credible response to end-stage heart failure:** CARMAT aims to eventually provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.

**The result of combining two types of unique expertise:** the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.

**Imitating the natural heart:** given its size, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming the necessary clinical trials are successful, potentially benefit the lives of thousands of patients a year with no risk of rejection and with a good quality of life.

---

<sup>1</sup> For further information, please refer to the 6<sup>th</sup> Shareholder Newsletter, which is available on the Company's website [www.carmatsas.com](http://www.carmatsas.com), in the Investors / Documentation / Shareholder Newsletter section.

**A project leader acknowledged at a European level:** with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million.

**Strongly committed, prestigious founders and shareholders:** [Airbus Group](#), Professor [Alain Carpentier](#), the [Centre Chirurgical Marie Lannelongue](#), [Truffle Capital](#), a leading European venture capital firm, and the thousands of institutional and individual shareholders who have placed their trust in CARMAT.

**For more information:** [www.carmatsa.com](http://www.carmatsa.com)



**Disclaimer**

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. The Company's objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.

No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the *Document de Référence* filed with *the Autorité des Marchés Financiers* under number D.14-0145 on March 17, 2014 and the *Note d'Opération* that was approved with visa no. 11-308 on July 11, 2011, changes in economic conditions, the financial markets or the markets in which CARMAT operates. In particular, no guarantee can be given concerning the Company's ability to finalize the development, validation and industrialization of the prosthesis and the equipment required for its use, to manufacture the prostheses, satisfy the requirements of the ANSM, enroll patients, obtain satisfactory clinical results, perform the clinical trials and tests required for CE marking and to obtain the CE mark. CARMAT products are currently exclusively used within the framework of clinical trials. They are not available outside these trials or for sale.



**CARMAT**  
**Marcello Conviti**  
CEO

**Patrick Coulombier**  
COO

**Valérie Leroy**  
Director of Marketing  
& Investor Relations

Tel.: +33 (0)1 39 45 64 50  
[contact@carmatsas.com](mailto:contact@carmatsas.com)

**Alize RP**  
Press Relations

**Caroline Carmagnol**

Tel.: +33 (0)1 70 22 53 90  
[caroline@alizerp.com](mailto:caroline@alizerp.com)



**NewCap**  
Financial Communication  
and Investor Relations

**Dusan Oresansky**  
**Emmanuel Huynh**

Tel.: +33 (0)1 44 71 94 94  
[carmat@newcap.fr](mailto:carmat@newcap.fr)

Name: **CARMAT**  
ISIN code: **FR0010907956**  
Ticker: **ALCAR**